These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 16466780)
1. Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus. Ringwald J; Buettner S; Zimmermann R; Weisbach V; Strasser E; Eckstein R; Eckel K; Manger K Thromb Res; 2007; 119(1):129-31. PubMed ID: 16466780 [No Abstract] [Full Text] [Related]
2. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536 [TBL] [Abstract][Full Text] [Related]
3. Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Kilicarslan A; Yavuz B; Guven GS; Atalar E; Sahiner L; Beyazit Y; Kekilli M; Ozer N; Oz G; Haznedaroglu IC; Sozen T Blood Coagul Fibrinolysis; 2008 Jun; 19(4):310-4. PubMed ID: 18469553 [TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. Radu CM; Spiezia L; Campello E; Gavasso S; Woodhams B; Simioni P Thromb Res; 2013 Oct; 132(4):484-6. PubMed ID: 24028756 [No Abstract] [Full Text] [Related]
5. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Mosnier LO; Bouma BN Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2445-53. PubMed ID: 16960106 [TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Rooth E; Wallen H; Antovic A; von Arbin M; Kaponides G; Wahlgren N; Blombäck M; Antovic J Blood Coagul Fibrinolysis; 2007 Jun; 18(4):365-70. PubMed ID: 17473579 [TBL] [Abstract][Full Text] [Related]
8. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692 [TBL] [Abstract][Full Text] [Related]
9. Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin. Matsuda J; Matsuyama A; Atsumi G; Ohkura N Blood Coagul Fibrinolysis; 2008 Jan; 19(1):66-9. PubMed ID: 18180618 [TBL] [Abstract][Full Text] [Related]
10. A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus. Palafox-Sánchez CA; Vázquez-Del Mercado M; Orozco-Barocio G; García-De la Torre I; Torres-Carrillo N; Torres-Carrillo NM; Illades-Aguiar B; Muñoz-Valle JF Clin Appl Thromb Hemost; 2009; 15(2):233-8. PubMed ID: 18818228 [TBL] [Abstract][Full Text] [Related]
11. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Vairaktaris E; Yapijakis C; Nkenke E; Vassiliou S; Vylliotis A; Nixon AM; Derka S; Ragos V; Spyridonidou S; Tsigris C; Neukam FW; Patsouris E Am J Hematol; 2007 Nov; 82(11):1010-2. PubMed ID: 17636471 [TBL] [Abstract][Full Text] [Related]
12. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study. Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284 [TBL] [Abstract][Full Text] [Related]
13. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573 [TBL] [Abstract][Full Text] [Related]
14. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Mok CC Scand J Rheumatol; 2006; 35(2):85-95. PubMed ID: 16641040 [TBL] [Abstract][Full Text] [Related]
15. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. Nielsen VG; Steenwyk BL; Gurley WQ J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938 [TBL] [Abstract][Full Text] [Related]
16. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767 [TBL] [Abstract][Full Text] [Related]
17. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW; Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944 [TBL] [Abstract][Full Text] [Related]
18. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Nojima J; Iwatani Y; Ichihara K; Tsuneoka H; Ishikawa T; Yanagihara M; Takano T; Hidaka Y Thromb Res; 2009 May; 124(1):127-31. PubMed ID: 19128822 [TBL] [Abstract][Full Text] [Related]